← Emergent BioSolutions Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $488.8m | $560.9m | $782.4m | $1.1b | $1.6b | $1.8b | $1.1b | $1.0b | $1.0b | $742.9m | |
| Cost of Revenue | $131.3m | $195.7m | $322.3m | $433.5m | $524.0m | $1.1b | $693.1m | $705.4m | $844.3m | $326.2m | |
| Gross Profit (derived) | $357.5m | $365.2m | $460.1m | $672.5m | $1.0b | $701.0m | $383.0m | $317.6m | $199.3m | $416.7m | |
| Operating Costs and Expenses | — | — | — | — | $1.1b | $1.4b | $1.3b | $1.8b | $1.2b | $642.8m | |
| Operating Expenses | — | — | $692.6m | $991.9m | — | — | — | — | — | — | |
| Operating Income (Loss) | $105.5m | $124.3m | $89.8m | $114.1m | $433.8m | $352.6m | ($170.0m) | ($726.4m) | ($108.7m) | $100.1m | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $6.9m | $8.6m | $25.0m | $58.7m | $59.8m | $58.5m | $59.9m | $65.6m | $65.1m | $65.1m | |
| Goodwill, Impairment Loss | — | — | — | $0 | $0 | $41.7m | $6.7m | $218.2m | $0 | $0 | |
| Income (Loss) Attributable to Parent, before Tax | — | — | — | $77.4m | $407.2m | $314.4m | ($218.6m) | ($731.2m) | ($142.9m) | $82.8m | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $63.3m | $80.7m | $71.0m | $63.9m | $362.0m | $112.0m | ($442.6m) | ($805.1m) | ($355.5m) | ($4.7m) | |
| Income (Loss) from Continuing Operations, Per Basic Share | $2 | $2 | $1 | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | $1 | $2 | $1 | — | — | — | — | — | — | — | |
| Operating Lease, Lease Income | — | — | — | — | $30.5m | $62.1m | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | $314.4m | ($219.0m) | ($731.2m) | ($142.9m) | $82.8m | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | $62.5m | $82.6m | $62.7m | — | — | — | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | ($10.7m) | $0 | $0 | — | — | — | — | — | — | — | |
| Net Income (Loss) Attributable to Parent | $51.8m | $82.6m | $62.7m | $54.5m | $305.1m | $230.9m | ($211.6m) | ($760.5m) | ($190.6m) | $52.6m | |
| Earnings Per Share, Basic | $1.29 | $1.98 | $1.25 | $1.06 | $5.79 | $4.32 | ($4.22) | ($14.85) | ($3.60) | $0.98 | |
| Earnings Per Share, Diluted | $1.13 | $1.71 | $1.22 | $1.04 | $5.67 | $4.27 | ($4.22) | ($14.85) | ($3.60) | $0.93 | |
| Weighted Average Number of Shares Outstanding, Basic | 40.2m | 41.8m | 50.1m | 51.5m | 52.7m | 53.5m | 50.1m | 51.2m | 53.0m | 53.5m | |
| Weighted Average Number of Shares Outstanding, Diluted | 49.3m | 50.3m | 51.4m | 52.4m | 53.8m | 54.1m | 50.1m | 51.2m | 53.0m | 56.7m | |
| Research and Development Expense | $108.3m | $97.4m | $142.8m | $226.2m | $234.5m | $234.0m | $188.3m | $111.4m | $70.7m | $53.2m | |
| Selling, General and Administrative Expense | $143.7m | $143.5m | $202.5m | $273.5m | $303.3m | $348.4m | $339.5m | $368.4m | $308.0m | $186.1m | |
| Other Nonoperating Income (Expense) | $263k | ($815k) | $1.6m | $1.7m | $4.7m | ($3.7m) | ($11.7m) | $8.9m | $12.5m | $54.2m | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $71.0m | $59.3m | |
| Current Income Tax Expense (Benefit) | $32.6m | $32.8m | $10.2m | $24.0m | $104.5m | $39.6m | $26.3m | $36.6m | $53.2m | $34.1m | |
| Interest Expense | $7.6m | $6.6m | $9.9m | $38.4m | $31.3m | $34.5m | $37.3m | $87.9m | — | — | |
| Income Tax Expense (Benefit) | $36.7m | $36.0m | $18.8m | $22.9m | $102.1m | $83.5m | ($7.4m) | $29.3m | $47.7m | $30.2m | |
| Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement | — | — | — | — | ($1.0m) | $0 | $400k | $0 | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.